Optimizing IBS Treatment in Pharmacy Practice
Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are highly prevalent gastrointestinal disorders that can have a major impact on patients’ quality of life, work productivity and healthcare costs.
This program supports pharmacists in optimizing their management of chronic idiopathic constipation (CIC), constipation-predominant IBS (IBS-C), and diarrhea-predominant IBS (IBS-D) within pharmacy practice. Using case studies, the program will review recommendations supported by the Canadian Association of Gastroenterology (CAG). It will also encourage pharmacists to recognize red flags and to also recognize the need for timely escalation of treatment in people who continue to have symptoms despite the use of OTC medications.
This program has received an educational grant or in-kind support from Allergan.
This continuing education lesson is designed primarily for pharmacists and has been accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 1.25 CEU(s). CCCEP File Number: 1066-2021-3250-I-P
Louis Liu, MD, PhD, FRCPC, CAGFÀ
Carlene Oleksyn, B. Pharm., CDE
John Papastergiou, BSc, BScPhm
Upon completion of this continuing education program, participants will be able to:
- Counsel patients on OTC and pharmacologic treatment options for CIC, IBS-C, and IBS-D, in line with CAG guidelines
- Identify patients with inadequately controlled IBS who may benefit from appropriate treatment escalation strategies
- Recognize red flags that warrant referral to a family physician